RFESD

Across TCGA pan-cancer cohorts, RFESD RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated RFESD data layer compared with 2 for mutation status and 4 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher RFESD RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RFESD expression acts as an unfavorable survival marker, although some lineages such as MESO and ACC show a favorable association.

KIRP, LGG, and KICH are the cancer types where RFESD RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	DFS	Tertile	All	0.810	0.957	.001	113	view →
LGG	DFS	Median	All	0.636	0.839	<.001	54	view →
KICH	DFS	Quartile	II,III,IV	0.377	0.937	.002	52	view →
MESO	OS	Quartile	All	0.508	0.269	.007	37	view →
LIHC	DFS	Tertile	All	0.462	0.648	<.001	35	view →
SCLC	DFS	Quartile	All	0.276	0.558	.012	33	view →
STAD	OS	Quartile	IV	0.142	0.684	.002	32	view →
UVM	DFS	Median	III,IV	0.208	0.740	.006	22	view →
ACC	DFS	Median	III,IV	0.570	0.123	.007	16	view →
LUAD	OS	Median	III,IV	0.512	0.794	.001	16	view →
ESCA	OS	Tertile	All	1.000	0.607	.036	10	view →
THCA	DFS	Tertile	IV	0.417	0.865	.004	8	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

RFESD–KIRP (DFS)

Open the KIRP breakdown →